Flu vaccine injected into melanoma tumors for stage I-IV
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether injecting a flu vaccine directly into melanoma tumors helps shrink them. It is for people with stage I to IV melanoma who have at least one tumor that can be injected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 99 years old
- You have melanoma that started in the skin, confirmed by a past biopsy
- You have at least one melanoma tumor that can be felt or seen on ultrasound and is at least 1 cm (about the size of a pea)
- You are generally well enough to do daily activities (ECOG 0-1)
- You are not allergic to flu vaccines, do not have active autoimmune disease, and have not had other melanoma treatments in the last 6 months
- If you could become pregnant, you agree to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This study tests whether injecting the seasonal flu vaccine directly into a skin cancer tumor can help the immune system attack it. You would receive the injection before your scheduled surgery to remove the cancer.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Hear when a new Clinical Stage I Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.